KEGG   NETWORK: N10024
Entry
N10024                      Network                                

Name
Tyrosine kinase inhibitor to MET exon 14 skipping
Definition
(Capmatinib,Tepotinib) -| MET*
  Expanded
(D10891,D11073) -| 4233v4
Class
nt06210 ERK signaling
nt06266 Non-small cell lung cancer
nt06214 PI3K signaling
Type
Drug target
Gene
4233  MET; MET proto-oncogene, receptor tyrosine kinase
Variant
4233v4  MET exon 14 skipping
Perturbant
D10891  Capmatinib hydrochloride
D11073  Tepotinib hydrochloride
Reference
  Authors
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C
  Title
cMET Exon 14 Skipping: From the Structure to the Clinic.
  Journal
J Thorac Oncol 11:1423-32 (2016)
DOI:10.1016/j.jtho.2016.05.005
Reference
  Authors
Drilon A, Cappuzzo F, Ou SI, Camidge DR
  Title
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
  Journal
J Thorac Oncol 12:15-26 (2017)
DOI:10.1016/j.jtho.2016.10.014
LinkDB

DBGET integrated database retrieval system